Table 5.
Comparison of the sums of withdrawal symptoms according to BWSQ between the melatonin (CRM) and the placebo groups at week 1, month 1 and month 6
| Sum of withdrawal symptoms | Week 1 | Month 1 | Month 6 | P1 | P2 | P3 | |||
|---|---|---|---|---|---|---|---|---|---|
| n | Median (IQR) [Range] | n | Median (IQR) [Range] | n | Median (IQR) [Range] | ||||
| CRM group | 46 | 4.1 (3.6) [0–14] | 43 | 3.2 (2.9) [0–13] | 44 | 3.6 (3.0) [0–14] | 0.886 | 0.323 | 0.198 |
| Placebo group | 46 | 4.0 (4.9) [0–22] | 42 | 3.2 (3.8) [0–13] | 43 | 3.1 (2.8) [0–10] | |||
IQR, interquartile range; P1, statistical significance for group × time interaction effect, repeated measures analysis of variance; P2, statistical significance for group effect; adjusted for group, repeated measures analysis of variance; P3, statistical significance for time effect, adjusted for time, repeated measures analysis of variance.